NFL Biosciences SAS (ALNFL) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of NFL Biosciences SAS stock €0.22, price €0.39, that is 42.9% below the price, quality 38 out of 100. Rating: strongly overvalued. Calculated from audited financials with 2 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.
How to read this chart
60‑month range €0.3415 – €4.75 · fair‑value band €0.2000 – €0.2600 · the €0.3850 price screens above the €0.2200 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.
Follow NFL Biosciences SAS in your weekly email
Every Wednesday you see whether NFL Biosciences SAS is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
NFL Biosciences SA, a biotechnology company, engages in the development of botanical drugs in France.
Show moreShow less
The company's pipeline includes NFL-101, a drug candidate for smoking cessation, currently under Phase 2b clinical trials; and NFL-301, a drug candidate for reducing alcohol consumption which is in preclinical stage.
It has scientific collaboration with McLean Hospital to deepen the understanding of the mechanism of action of NFL-101, its proprietary botanical drug candidate for smoking cessation. NFL Biosciences SA was incorporated in 2006 and is headquartered in Castelnau-le-Lez, France.
Stock analysis
NFL Biosciences SAS (ALNFL) currently trades at €0.3850, while our model-based Fair Value estimate is €0.2200, 43% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 2 models at a data quality of 88/100, which puts the data coverage at low.
Scenario range: €0.2000 (bear) to €0.2600 (bull), the price of €0.3850 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
NFL Biosciences SAS reported revenue of €0 in FY2025 versus €39 in FY2021. Reported net income was −€3.3M in FY2025.
Our AI-assisted moat analysis scores the competitive advantage at 29 out of 100 (low confidence).
What moves the price
The share trades about 77% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −43%, ALNFL screens richer than that median.
Fair Value models
Bear€0.2000Fair Value €0.2200Bull€0.2600
Price €0.3850 · Downside -42.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.23/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−100.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.7%
’20
’21
’23
’24
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−10,600,933.3% (2020) → −6,065,415.2% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+21.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (euro area: IMF forecast 2.2% a year to 2030, 2.6% from 2016 to 2025) that is about +18.6% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score38 · Below median
Fair Value upside−36.0% · Above median
Profitability
Return on assets−90.6% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)18.7% · Above median
Balance sheet
Debt / equity1.42× · Highest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B14.58× · Priciest 25%
Price / free cash flow (fiscal year)42.6× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)94· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)29· sector 97
DIVIDEND (yield)0· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "NFL Biosciences SAS Fair Value". https://www.fairvalue-calculator.com/stock/ALNFL
Frequently asked questions
Is NFL Biosciences SAS (ALNFL) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of €0.2200 versus a price of €0.3850, about 43% lower (overvalued).
What is the fair value of ALNFL?
Our model-based fair value for NFL Biosciences SAS is €0.2200 (as of Nov 4, 2026), built from audited fundamentals. The current price: €0.3850.
What is the quality score of ALNFL?
NFL Biosciences SAS has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for NFL Biosciences SAS (ALNFL)?
Our model-based price target is the fair value of €0.2200 (as of Nov 4, 2026) from 2 valuation models. Cautious scenario €0.2000, optimistic scenario €0.2600. It is a calculation from audited fundamentals, not an analyst target.
What is the NFL Biosciences SAS stock forecast for 2026?
Our models put fair value at €0.2200, about 43% lower versus a price of €0.3850 (overvalued). Cautious scenario €0.2000, optimistic scenario €0.2600. The calculation is refreshed regularly with new filings.
What is the revenue of NFL Biosciences SAS (ALNFL)?
NFL Biosciences SAS reported trailing-twelve-month revenue of about €3.1K (latest available figure, as of Nov 4, 2026).
What growth is priced into NFL Biosciences SAS (ALNFL)?
For today's price to be fair in a discounted-cash-flow model, NFL Biosciences SAS would have to grow free cash flow by +21.2 % per year for five years (discount rate 11.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew +97.9 % per year. As of Nov 4, 2026.
What discount rate (WACC) does the fair value of ALNFL use?
Our models discount NFL Biosciences SAS at 11.0 %: a base by market capitalisation (nano), damped by beta 1.28, country premium for France. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For NFL Biosciences SAS that is +21.2 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.0 %) and the same formula as our fair value.
How much growth has NFL Biosciences SAS (ALNFL) delivered so far?
Over the past 4 years revenue at NFL Biosciences SAS grew +97.9 % a year. The price currently implies free-cash-flow growth of +21.2 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of NFL Biosciences SAS (ALNFL) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into NFL Biosciences SAS (+21.2 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of NFL Biosciences SAS (ALNFL)?
The free-cash-flow yield on the price is 2.15 %: that much free cash flow NFL Biosciences SAS produces per unit of market value. When it exceeds the discount rate of our models (11.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of NFL Biosciences SAS (ALNFL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For NFL Biosciences SAS it is €0.2200 per share (as of Nov 4, 2026), against a price of €0.3850. It is the blended result of 2 valuation models in 2 families (DCF Models, Growth DCF).
Is NFL Biosciences SAS stock overvalued or undervalued in 2026?
As of Nov 4, 2026, ALNFL trades above its calculated fair value: price €0.3850, fair value €0.2200, a gap of about −43% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ALNFL?
No. The price is what the market pays today (€0.3850); the fair value is what the company's own numbers justify (€0.2200). For NFL Biosciences SAS the two are €0.1650 per share apart. That gap is exactly why we show both numbers side by side.
How much is NFL Biosciences SAS worth?
The market values NFL Biosciences SAS at about €4.9M (market capitalisation, as of Nov 4, 2026). Per share that is €0.3850; our models calculate a fair value of €0.2200 per share.
What do the bullish and bearish scenarios say about ALNFL?
Our models span a range for NFL Biosciences SAS: cautious scenario €0.2000, base €0.2200, optimistic €0.2600 per share (as of Nov 4, 2026, price €0.3850). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of NFL Biosciences SAS (ALNFL)?
Balance-sheet figures for NFL Biosciences SAS (as of Nov 4, 2026): debt of 1.42 per unit of equity. They feed the Quality Score of 38/100, which measures business quality independently of the share price.
How far is ALNFL from its 52-week high?
NFL Biosciences SAS trades at €0.3850, about 77% below its 52-week high of €1.65 and 13% above the low of €0.3415 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of €0.2200 is for.
Which stocks are comparable to NFL Biosciences SAS?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is NFL Biosciences SAS stock attractive at the current price?
The data as of Nov 4, 2026: price €0.3850, calculated fair value €0.2200 (−43%), Quality Score 38/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ALNFL calculated?
We run NFL Biosciences SAS through 2 models from 2 families: DCF Models, Growth DCF. Every model gets the same audited fundamentals; the fair value of €0.2200 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. NFL Biosciences SAS itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of NFL Biosciences SAS (ALNFL)?
The closing price on Nov 9, 2026 was €0.3850. Our model-based fair value is €0.2200, about 43% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with NFL Biosciences SAS right now?
The price sits above even our optimistic bull case (€0.2600). The favourable scenario is already priced in. Weak quality (38/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of NFL Biosciences SAS
How large is the market capitalisation of NFL Biosciences SAS (ALNFL)?
The market capitalisation of NFL Biosciences SAS is €4.9M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of NFL Biosciences SAS (ALNFL)?
Earnings per share at NFL Biosciences SAS are €−0.2300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of NFL Biosciences SAS (ALNFL)?
The return on equity (ROE) of NFL Biosciences SAS is −517% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of NFL Biosciences SAS (ALNFL)?
On an EBIT basis the return on assets of NFL Biosciences SAS is −89.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of NFL Biosciences SAS (ALNFL)?
The operating margin of NFL Biosciences SAS is −63,809% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at NFL Biosciences SAS (ALNFL)?
Revenue at NFL Biosciences SAS is growing +18.7% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net cash does NFL Biosciences SAS (ALNFL) hold?
NFL Biosciences SAS holds more cash than debt, €1.4M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch NFL Biosciences SAS in the live analysis
One click puts NFL Biosciences SAS on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 4, 2026